JSA advised Zentiva on its 100% acquisition by GTCR from its existing investor, Advent International.
GTCR, a Chicago-based private equity firm, has entered into definitive agreements to acquire generic drugmaker Zentiva from Advent International in a transaction valued at €4.1 billion (approx. ₹36,600 crore).
Zentiva is a leading pharmaceutical company focused on developing and manufacturing high-quality, affordable medicines, serving over 100 million people across more than 30 countries. In India, Zentiva operates a manufacturing facility in Ankleshwar, Gujarat.
GTCR brings deep sector expertise across multiple industries, including Financial Services & Technology, Healthcare, Technology, Media & Telecommunications, and Growth Business Services.
JSA Team
The transaction was led by Partner Sidharrth Shankar, with support from the Mergers & Acquisitions team comprising Partners Prakriti Jaiswal and Dhruv Malhotra, and Senior Associate Eksha Narayan.
Prakriti specialises in mergers & cross border investments & acquisitions and private equity transactions. Her experience includes rendering advisory and structuring services on a variety of transactions including acquisitions of shares & business, private equity investments, joint ventures and corporate advisory.